Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study - Summary - MDSpire
Advertisement
Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study
To evaluate the effectiveness and safety of baricitinib and ritlecitinib in patients with severe alopecia areata treated in routine clinical practice.
Approach:
Study Design: Monocentric retrospective observational study conducted at the Dermatology Unit of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy.
Population: Included adolescent and adult patients diagnosed with severe alopecia areata, treated with baricitinib 4 mg or ritlecitinib 50 mg.
Data Collection: Retrospective data collected from electronic medical records, including demographic, clinical variables, and disease-related characteristics.
Key Findings:
Both baricitinib and ritlecitinib showed progressive improvement in scalp hair regrowth over 1 year.
Comparable Severity of Alopecia Tool (SALT) ≤ 20 response rates at weeks 16 and 52 for both treatments.
Eyebrow and eyelash involvement improved progressively in both groups with no significant differences.
Baricitinib had more frequently reported non-severe adverse events, mainly weight gain, but treatment discontinuation due to adverse events was infrequent and comparable between groups.
Interpretation:
Both baricitinib and ritlecitinib are effective and safe for treating severe alopecia areata, with similar outcomes in hair regrowth and safety profiles.
Limitations:
Single-center study may limit generalizability.
Retrospective design may introduce bias.
Conclusion:
The study provides real-world evidence on the effectiveness and safety of baricitinib and ritlecitinib in severe alopecia areata.
by Francesco D’Oria, Sara Di Giulio, Luciano Ibba, Costanza Falcidia, Giulio Foggi, Carlo Alberto Vignoli, Paola Facheris, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Alessandra Narcisi, Mario Valenti
